VivoSeq
Infectious Disease

Lassa Fever

10

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Lassa fever is an early-stage landscape with 10 programs across 2 companies. The most active players are Arisan Therapeutics, Inc., Appili Therapeutics Inc.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

33/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Arisan Therapeutics, Inc.

4 programs

Phase 2A

Appili Therapeutics Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Terminated1 · 14%
Completed1 · 14%
Active, not recruiting1 · 14%
Suspended1 · 14%

Clinical Trials

Trial Activity

7 trials

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
Recruiting·IInternational AIDS Vaccine Initiative·Phase 2·NCT05868733·612 enrolled
LAssa Fever Adjunct Treatment With DEXamethasone
Recruiting·BBernhard Nocht Institute for Tropical Medicine·Phase 2·NCT06222723·42 enrolled
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Recruiting·IIrrua Specialist Teaching Hospital·Phase 2/3·NCT06212336·1,755 enrolled
DMID 23-0015; Lassa Fever CVD 1000
Active, not recruiting·WWilbur Chen, MD, MS·Phase 1·NCT06546709·55 enrolled
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
Completed·BBernhard Nocht Institute for Tropical Medicine·Phase 2·NCT04907682·40 enrolled
A Phase 2 Study to Evaluate Safety, Tolerability, And Virologic Efficacy of ARN-75039 For the Treatment of Lassa Fever in West Africa
Suspended·AArisan Therapeutics, Inc.·Phase 2·NCT07419373·135 enrolled
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever
Terminated·UUniversity of Oxford·N/A·NCT03889106·2 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)